

Lipid Lowering Agents
Evkeeza (evinacumab-dgnb)
Leqvio (inclisiran)
Effective 06/01/2025

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical and Specialty Medications		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
Exceptions	Non-Specialty Medications		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
	Leqvio is also available on the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		
	Additional agents from this class are available through the pharmacy benefit. Please see the MassHealth Drug List for coverage and criteria.		

Overview

Evkeeza is an angiopoietin-like 3 (ANGPTL3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH).

Leqvio is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

Evkeeza (evinacumab-dgnb)

ALL of the following:

1. Diagnosis of HoFH confirmed by **ONE** of the following:
 - a. Laboratory test confirming genetic mutation associated with HoFH including low density lipoprotein receptor (LDLR) mutations, PCSK9 mutations and familial defective apoB mutations
 - b. **BOTH** of the following:

- i. Baseline LDL-C \geq 400 mg/dL
 - ii. Current LDL-C \geq 100 mg/dL
- c. **ONE** of the following:
 - i. Member had evidence of xanthoma before 10 years of age
 - ii. Evidence of HeFH in both parents
- 2. Member is \geq 5 years of age
- 3. Prescriber is a specialist (e.g. cardiologist, vascular neurologist, lipid lowering specialist, endocrinologist) or consultation notes from a specialist regarding the use of the agent are provided
- 4. **ONE** of the following:
 - a. Agent to be used as add-on therapy with a high-intensity statin, ezetimibe, and PCSK9 inhibitor
 - b. Contraindication or other well-defined clinical rationale for omitting one or more of the standard lipid-lowering therapies: statin, ezetimibe, and PCSK9 inhibitors
- 5. Member's current weight (use to verify correct dosing)
- 6. Appropriate dosing

Leqvio (inclisiran)

ALL of the following:

- 1. Diagnosis is hypercholesterolemia with **ONE** of the following:
 - a. For members with a diagnosis of HeFH, current LDL-C is \geq 70 mg/dL
 - b. For members without a previous history of a cardiovascular event (with or without HeFH or HoFH), **BOTH** of the following:
 - i. **ONE** of the following:
 - 1. Member has Type 2 diabetes
 - 2. Member has \geq 20% 10-year risk of a cardiovascular event (Framingham Risk Score for Cardiovascular Disease or equivalent)
 - ii. Current LDL-C is \geq 55 mg/dL
 - c. For members with a previous history of a cardiovascular event, current LDL-C is \geq 55 mg/dL
- 2. Member is \geq 18 years of age
- 3. Prescriber is a specialist (e.g. cardiologist, vascular neurologist, lipid lowering specialist, endocrinologist) or consultation notes from a specialist regarding the use of the agent are provided
- 4. Inadequate response (defined as \geq the last 3 months) or adverse reaction to **ONE** or contraindication to **BOTH** of the following*:
 - a. Praluent (alirocumab)
 - b. Repatha (evolocumab)
- 5. **ONE** of the following†:
 - a. Inadequate response (defined as \geq the last 3 months) to combination therapy with a high intensity statin and ezetimibe
 - b. Adverse reaction or contraindication to ezetimibe AND inadequate response (defined as \geq the last 3 months) to high intensity statin monotherapy
 - c. Adverse reaction to ONE high intensity statin or contraindication to ALL high intensity statins
- 6. Appropriate dosing

*Requests looking to bypass the required trial with Praluent (alirocumab) or Repatha (evolocumab) may be approved if the prescriber documents concerns with the member using self-injections (due to non-adherence or low health literacy)

† If the prescriber documents that the member has experienced an adverse reaction to a high intensity statin or has a contraindication to high intensity statins, requests may be approved without the requirement for ezetimibe monotherapy



Continuation of Therapy

Reauthorization should be reviewed for the following information:

Evkeeza (evinacumab-dgnb)

1. **ONE** of the following:
 - a. Decrease in LDL-C from baseline and the member appears to be adherent to the regimen.
 - b. Decrease in LDL-C from baseline and evidence of non-adherence to one or more agent(s) in the regimen.
2. Updated member weight (use to verify correct dosing; may take this information over the phone if missing on PA request)

Leqvio (inclisiran)

1. Member appears to be adherent to Leqvio, statin and/or ezetimibe therapy (consistent with regimen noted on initial approval) (at least 60 days of therapy within the last 90 days for the statin and ezetimibe)
2. **ONE** of the following:
 - a. Decrease in LDL-C from baseline and the member appears to be adherent to the regimen.
 - b. Decrease in LDL-C from baseline and evidence of non-adherence.
 - c. If there is no decrease or an increase in LDL-C, or if an updated LDL-C is not provided and there is evidence of non-adherence.

Limitations

1. Initial approvals will be granted for **6 months**.
2. Reauthorizations will be granted for the following:
 - a. Decrease in LDL-C from baseline and member is adherent: **12 months**.
 - b. Decrease in LDL-C from baseline and non-adherence: **6 months**.
 - c. No decrease or an increase in LDL-C or updated LDL-C not provided and non-adherence: **6 months**.

Appendix

I. Special Considerations in Lipid Lowering Therapy

Contraindication to Statin Therapy
The following should be considered for approval when reviewing requests: <ul style="list-style-type: none">• Elevated serum transaminases with statin use• Elevated baseline serum transaminases (due to liver disease or other etiology)<ul style="list-style-type: none">○ All statins are cautioned in patients with liver disease; however, pravastatin has been studied in this population and is generally recommended at low doses

References

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002 Dec 17;106(25):3143-421.
2. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Nov 7.



3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. *Circulation*. 2018 Nov 10;CIR0000000000000624.
4. Rosenson RS. Statins: Actions, side effects, and administration. In: Basow DS (Ed). UpToDate [database on the Internet]. Waltham (MA): UpToDate; 2019 [cited 2019 April 19]. Available from: <http://www.uptodate.com/utd/index.do>.
5. Evkeeza [package insert on the internet]. Tarrytown (NY): Regeneron; 2025 [cited 2025 March 21]. Available from: <https://evkeeza.com>.
6. Leqvio [package insert]. East Hanover (NJ): Novartis; 2024 July.
7. FDA approves add-on therapy for patients with genetic form of severely high cholesterol [press release on the Internet]. Rockville (MD): Food and Drug Administration (US); 2021 Apr 1 [cited 2021 Sep 10]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-add-therapy-patients-genetic-form-severely-high-cholesterol-0>
8. FDA Approves First of Novel Cholesterol-Lowering Drugs [press release on the Internet]. American College of Cardiology; 2015 July 24 [cited 2019 Apr 19]. Available from: http://www.acc.org/latest-in-cardiology/articles/2015/07/24/16/01/fda-approves-first-of-novel-cholesterol-lowering-drugs?w_nav=Tab
9. Micromedex Healthcare Series [database on the Internet] Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2021 Sep 8]. Available from: <http://www.thomsonhc.com/>.
10. Drug information. In: Basow DS (Ed). UpToDate [database on the Internet]. Waltham (MA): UpToDate; 2021 [cited 2021 Sep 8]. Available from: <http://www.uptodate.com/utd/index.do>
11. 58.Genetic Testing for Familial Hypercholesterolemia. [webpage on the Internet]. Atlanta (GA): Centers for Disease Control and Prevention; February 2022 [cited 2022 Mar 17]. Available from: https://www.cdc.gov/genomics/disease/fh/testing_FH.htm
12. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in Young Committee of Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, Council on Functional Genomics and Translational Biology, and Council on Lifestyle and Cardiometabolic Health. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. *Circulation*. 2015 Dec 1;132(22):2167-92.
13. Rosenson RS, Durrington P. Familial hypercholesterolemia in adults: Overview. In: Basow DS (Ed). UpToDate[database on the internet]. Waltham (MA): UpToDate; 2022 [cited 2022 Mar 17]. Available from: <http://www.uptodate.com/utd/index.do>
14. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al, on behalf of the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care*. 2023 Jan 1;46(Suppl 1):S158-S190.

Review History

02/08/2023 - Reviewed and created for Feb P&T; matched MH UPPL criteria to be in compliance with Masshealth unified formulary requirements. Criteria was named as Lipid Lowering Agents. Note: Praluent and Repatha was combined to this criteria. Effective 4/1/23.

07/12/23 – Reviewed and updated for P&T. Formatting updates to drug table. Clarified approvable diagnoses. Praluent and Repatha criteria updated to become less restrictive. Appendix criteria for special populations who are statin intolerant was removed and now combined with its respective criteria. Low cost alternative trials language have been simplified throughout the policy. Praluent and Repatha trial may be bypassed for Leqvio if there are concerns with member using self injections. Caduet®(amlodipine/atorvastatin) was updated to only require medical necessity for use of the combination product instead of the commercially available separate



agents. Evkeeza had an age expansion to members aged 5 and older. New drug, Atorvaliq, was added. Brand preferred and mandatory generic language was added under Limitations. Effective 7/31/23

09/13/23 – Reviewed and updated for P&T. Leqvio has been added to pharmacy benefit with PA and will remain on medical benefit with PA. Effective 10/2/23

05/15/25 – Reviewed and updated for P&T. Performed annual medical criteria review. Policy has been updated to better reflect agents with prior authorization on medical benefit. All agents except for Evkeeza and Leqvio were pharmacy benefit only and thus have been removed. Updated formatting & references accordingly. Criteria for Leqvio was updated to reflect expanded indication for members with increased cardiovascular risk. Effective 6/1/25

